Published in Vaccine Weekly, June 18th, 2008
Geron is currently testing GRN163L in four clinical trials with 15 U.S. medical centers recruiting patients with solid tumors, chronic lymphoproliferative disease, multiple myeloma and non-small cell lung cancer. New combination trials in breast cancer and multiple myeloma at additional trial sites are scheduled to initiate in the coming months. Geron is also conducting a multi-center Phase II trial of GRNVAC1, a telomerase therapeutic vaccine, in high risk acute myelogenous leukemia (AML)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-06-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.